The specter of generic challenges has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the future of similar drug holdings. While first years saw impressive gains, the intellectual property expiration has allowed the path for cheaper copies, likely lowering earnings and creating a real risk for s